Rapid detection of intracellular SH2D1A protein in cytotoxic lymphocytes from patients with X-linked lymphoproliferative disease and their family members

Blood

Volumn 105, Issue 8, 2005, Pages 3066-3071

  Tabata, Yasuhiro ^a   Villanueva, Joyce ^b   Lee, Susan Molleran ^b   Zhang, Kejian ^b   Kanegane, Hirokazu ^b   Miyawaki, Toshio ^b   Sumegi, Janos ^b   Filipovich, Alexandra H ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; CYTOTOXICITY; DATA ANALYSIS; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HETEROZYGOTE; HUMAN; INFANT; INTERMETHOD COMPARISON; LYMPHOCYTE SUBPOPULATION; LYMPHOPROLIFERATIVE DISEASE; MALE; NATURAL KILLER CELL; PATHOGENESIS; PRIORITY JOURNAL; SCHOOL CHILD; SH2 DOMAIN CONTAINING GENE 1A; STAINING; T LYMPHOCYTE; X CHROMOSOME LINKAGE; X CHROMOSOME LINKED DISORDER;

EID: 17044424680     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-09-3651     Document Type: Article

References (24)

1. Sumegi J, Huang D, Lanyi A, et al. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood. 2000;96:3118-3125.
2. Gaspar HB, Sharifi R, Gilmour KC, Thrasher AJ. X-linked lymphoproliferative disease: clinical, diagnostic and molecular perspective. Br J Haematol. 2002;119:585-595.
3. Imashuku S, Teramura T, Tauchi H, et al. Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica. 2004;89:183-188.
4. Gross TG, Filipovich AH, Conley ME, et al. Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): report from the XLP registry. Bone Marrow Transplant. 1996;17:741-744.
5. Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 1998;20:129-135.
6. Nichols KE, Harkin DP, Levitz S, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 1998;95:13765-13770.
7. Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 1998;395:462-469.
8. Sumegi J, SeemayerTA, Huang D, et al. A spectrum of mutations in SH2D1A that causes X-linked lymphoproliferative disease and other Epstein-Barr virus-associated illnesses. Leuk Lymphoma. 2002;43:1189-1201.
9. Gitmour KC, Cranston T, Jones A, et al. Diagnosis of X-linked lymphoproliferative disease by analysis of SLAM-associated protein expression. Eur J Immunol. 2000;30:1691-1697.
10. Morra M, Simarro-Grande M, Martin M, et al. Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients. J Biol Chem. 2001;276:36809-36816.
11. Shinozaki K, Kanegane H, Matsukura H, et al. Activation-dependent T cell expression of the X-linked lymphoproliferative disease gene product SLAM-associated protein and its assessment for patient detection. Int Immunol. 2002;14:1215-1223.
12. Yoshida N, Ishii E, Oshima K, et al. Engraftment and dissemination of T lymphocytes from primary haemophagocytic lymphohistiocytosis in SCID mice. Br J Haematol. 2003;121:349-358.
13. Parolini S, Bottino C, Falco M, et al. X-linked lymphoproliferative disease: 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med. 2000;192:337-346.
14. Nagy N, Cerboni C, Mattsson K, et al. SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines. Int J Cancer. 2000;88:439-447.
15. Nistala K, Gilmour KC, Cranston T, et al. X-linked lymphoproliferative disease: three atypical cases. Clin Exp Immunol. 2001;126:126-130.
16. Kogawa K, Lee SM, Villanueva J, Marmer D, Sumeji J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002;99:61-66.
17. Engel P, Eck MJ, Terhorst C. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol. 2003;3:813-821.
18. Kanegane H, Ito Y, Ohshima K, et al. X-linked lymphoproliferative syndrome presenting with systemic lymphocytic vasculitis. Am J Hematol. 2005;78:130-133.
19. Wada T, Schurman SH, Jagadeesh GJ, et al. Multiple patients with revertant mosaicism in a single Wiskott-Aldrich syndrome family. Blood. 2004;104:1270-1272.
20. Stephan V, Wahn V, Le Deist F, et al. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N Engl J Med. 1996;335:1563-1567.
21. Ariga T, Oda N, Yamaguchi K, et al. T-cell lines from 2 patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation. Blood. 2001;97:2896-2899.
22. Nagy N, Mattsson K, Maeda A, Liu A, Szekely L, Klein E. The X-linked lymphoproliferative disease gene product SAP is expressed in activated T and NK cells. Immunot Lett. 2002;82:141-147.
23. Hugle B, Suchowerskyj P, Hellebrand H, et al. Persistent hypogammaglobulinemia following mononucleosis in boys is highly suggestive of X-linked lymphoproliferative disease - report of three cases. J Clin Immunol. 2004;24:515-522.
24. Takei M, Ishiwata T, Mitamura K, et al. Decreased expression of signaling lymphocytic-activation molecule-associated protein (SAP) transcripts in T cells from patients with rheumatoid arthritis. Int Immunol. 2001;13:559-565.